An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses

Vaccine. 1995 Jan;13(1):54-60. doi: 10.1016/0264-410x(95)80011-2.

Abstract

We have developed a unique multiple step procedure to inactivate human immunodeficiency virus chemically with a very high safety margin while retaining antigenically active structural virion proteins, including gp120, in the final immunogen. The whole virus preparation (1-10 micrograms per dose) was highly immunogenic in a variety of small mammals and induced antibodies that recognized homologous and heterologous strains of HIV-1. Sera from immunized animals bound to peptides representing the entire sequence of the external glycoprotein gp120. Neutralizing antibodies active against the homologous immunizing strain and against heterologous HIV-1 strains were also elicited. Sera with virus neutralizing activity did not bind to MHC class I proteins derived from the human cell line used to grow the virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Amino Acid Sequence
  • Animals
  • Antibody Formation
  • Dose-Response Relationship, Immunologic
  • Guinea Pigs
  • HIV Envelope Protein gp120 / immunology*
  • HIV-1*
  • Molecular Sequence Data
  • Neutralization Tests
  • Peptides / immunology
  • Rabbits
  • Rats
  • Recombinant Proteins / immunology
  • Vaccines, Inactivated / immunology

Substances

  • AIDS Vaccines
  • HIV Envelope Protein gp120
  • Peptides
  • Recombinant Proteins
  • Vaccines, Inactivated